Physician profile
David E Lewis
NPI 1609218759
$20,297.94
in general payments reported to CMS, 2019-2025
61 companies · $7,210 in 2025
The $7,210 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $1,329 · 2021: $1,952 · 2022: $2,655 · 2023: $2,459 · 2024: $3,308 · 2025: $7,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,145 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,816 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,145.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,816.00 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,139.55 | 2024-2025 | Rexulti |
| Abbvie INC. | $2,398.55 | 2019-2025 | |
| Novo Nordisk INC | $1,288.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,158.64 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Pfizer INC. | $1,131.73 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $996.37 | 2020-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $635.39 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $595.18 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $584.53 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $564.41 | 2019-2025 | Zepbound, Mounjaro, Emgality |
| Merck Sharp & Dohme LLC | $559.08 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.93 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $355.73 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $307.53 | 2019-2023 | Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $306.25 | 2022-2025 | Caplyta |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.